A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children
NCT ID: NCT01734408
Last Updated: 2013-10-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
773 participants
INTERVENTIONAL
2012-11-30
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The phase II study of inactivated vaccine (vero cell) against EV71 has completed last month in Jiangsu Province in China. The data from the phase II study suggested that the inactivated EV71 vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese children and infants. But the antibody titer against EV71 was found decreased significantly at month 8 compared to that at day 56. Considering the similar dynamic trend had also been found in the antibody against poliovirus induced by polio vaccines, and whose immunization schedule contains a booster dose administrated at 1 to 1.5 year after the first 3 doses of fundamental immunity. In order to find a better immunization schedule for children, the investigators decided to perform this booster immunity trial among these children who had received two doses of EV71 vaccines (around one year after the fundamental immunity). The investigators do the recruitment among these children who had participated in the previous phase II trial and received EV71 vaccines, and randomize them in a ratio of 2:1 to receive either a booster dose of EV71 vaccines or placebo.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
alum-adjuvant 160U /0.5ml EV71 vaccine
A booster dose of alum-adjuvant 160U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
alum-adjuvant 160U /0.5ml
inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
placebo A
A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
0/0.5ml placebo
0/0.5ml placebo
alum-adjuvant 320U /0.5ml EV71 vaccine
A booster dose of alum-adjuvant 320U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
alum-adjuvant 320U /0.5ml
inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
placebo B
A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
0/0.5ml placebo
0/0.5ml placebo
alum-adjuvant 640U /0.5ml EV71 vaccine
A booster dose of alum-adjuvant 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
alum-adjuvant 640U /0.5ml
inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
placebo C
A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
0/0.5ml placebo
0/0.5ml placebo
adjuvant-free 640U /0.5ml EV71 vaccine
A booster dose of adjuvant-free 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
adjuvant-free 640U /0.5ml
inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
placebo D
A 0/0.5ml placebo in 80 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
0/0.5ml placebo
0/0.5ml placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
alum-adjuvant 160U /0.5ml
inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
alum-adjuvant 320U /0.5ml
inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
alum-adjuvant 640U /0.5ml
inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
adjuvant-free 640U /0.5ml
inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
0/0.5ml placebo
0/0.5ml placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy children as established by medical history and clinical examination
* The subjects' guardians are able to understand and sign the informed consent
* Subjects who can and will comply with the requirements of the protocol
* Subjects with temperature \<=37.0°C on axillary setting
Exclusion Criteria
* Subject who has a medical history of EV71-associated disease with specific laboratory evidence
* \<= 37 weeks gestation
* Subjects with a birth weight \<2.5 kg
* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine
* Family history of seizures or progressive neurological disease
* Family history of congenital or hereditary immunodeficiency
* Severe malnutrition or dysgenopathy
* Major congenital defects or serious chronic illness, including perinatal brain damage
* Autoimmune disease
* Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws
* Any acute infections in last 7 days
* Any prior administration of immunodepressant or corticosteroids in last 6month
* Any prior administration of blood products in last 3 month
* Any prior administration of other research medicines in last 1 month
* Any prior administration of attenuated live vaccine in last 14 days
* Any prior administration of subunit or inactivated vaccines in last 7 days, such as pneumococcal vaccine
* Under the anti-TB prevention or therapy
* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives
21 Months
51 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bejing Vigoo Biological Co., LTD
INDUSTRY
Jiangsu Province Centers for Disease Control and Prevention
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fengcai Zhu
vice director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jiangsu Provincial Center for Diseases Control and Prevention
Nanjing, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Shenyu W, Jingxin L, Zhenglun L, Xiuling L, Qunying M, Fanyue M, Hua W, Yuntao Z, Fan G, Qinghua C, Yuemei H, Xin Y, Huijie G, Fengcai Z. A booster dose of an inactivated enterovirus 71 vaccine in chinese young children: a randomized, double-blind, placebo-controlled clinical trial. J Infect Dis. 2014 Oct 1;210(7):1073-82. doi: 10.1093/infdis/jiu113. Epub 2014 Mar 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JSVCT005b
Identifier Type: -
Identifier Source: org_study_id